Raza, K <br/><br/>
Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis.  [electronic resource] 

 -  Annals of the rheumatic diseases  Jul 2006 
 - 946-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0003-4967 
<br/><br/><label>Standard No.: </label>10.1136/ard.2005.043638  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>Arteritis--drug therapy<br/>Cyclophosphamide--therapeutic use<br/>Endothelium, Vascular--drug effects<br/>Female<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Infliximab<br/>Laser-Doppler Flowmetry<br/>Male<br/>Methylprednisolone--therapeutic use<br/>Middle Aged<br/>Pilot Projects<br/>Statistics, Nonparametric<br/>Time Factors<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors